Utilico Insights - Jacqueline Broers assesses why Vietnam could be the darling of Asia for investors. Watch the full video here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksMgc Pharma Ltd Regulatory News (MXC)

Share Price Information for Mgc Pharma Ltd (MXC)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 22.00
Bid: 21.00
Ask: 23.00
Change: 0.00 (0.00%)
Spread: 2.00 (9.524%)
Open: 0.00
High: 0.00
Low: 0.00
Prev. Close: 22.00
MXC Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

ArtemiC Rescue First Delivery and March Revenue

7 Apr 2021 07:08

RNS Number : 6418U
MGC Pharmaceuticals Limited
07 April 2021
 

07 April 2021

ASX Code: MXC

LSE Code: MXC

MGC Pharmaceuticals

MGC Pharma completes delivery of first major ArtemiCTM Rescue order to Swiss PharmaCan AG, drives March to record quarter for MGC's product revenues

 

Key Highlights:

· In March 2021, the Company announced an initial purchase order for ArtemiCTM Rescue from Swiss PharmaCan AG (SPC), of approximately AUD425,000 (~ €275,000) wholesale revenue to MGC Pharma - with this first major batch order delivered to SPC in March.

 

· MXC delivers record quarterly revenue from its phytomedicine products of approximately AUD880,000, inclusive of the first bulk order of ArtemiCTM Rescue from SPC.

 

· The SPC Master Agreement signed includes a minimum wholesale order quantity to MGC Pharma of 40,000 units per quarter of ArtemiCTM Rescue.

 

· Swiss PharmaCan AG to exclusively distribute ArtemiCTM Rescue worldwide1, with specific focus on countries currently reporting high numbers of COVID-19 patients.

 

· Sales growth of the Company's pharma grade, cannabinoid products has continued in key markets including Australia in the first quarter of calendar 2021.

 

· Completion of the Medicinal Cannabis Clinics (MCC) acquisition starts to deliver operational synergies and broader Australian patient access including new sales pipeline.

 

MGC Pharmaceuticals Ltd (ASX, LSE: MXC, 'MGC Pharma' or 'the Company'), a European based bio-pharma company specialising in the production and development of phytocannabinoid-derived medicines, is pleased to announce it completed delivery of the first bulk order in March of ArtemiCTM Rescue to Swiss PharmaCan AG, equating to circa AUD425,000 (~ €275,000) wholesale production revenue to MGC Pharma.

Upon completion of manufacturing and delivery of this first ArtemiCTM Rescue bulk order, the Company successfully delivered a record quarter of sales revenues from its proprietary phytomedicine product line, with approximately AUD880,000 of revenue generated for the March 2021 quarter.

The month of March also delivered the best monthly sales revenue for the Company to date from its pharmaceutical grade phytomedicine products, with sales of the MP product line in Australia driving its best monthly unit sales to date with over 1,500 units sold. More details of the sales and revenue results will be detailed in the March quarterly activity report due out in the coming weeks.

Importantly, the Company has also been completing the operational integration of the MCC acquisition over the past few months and is now operating under MGC Pharma's management control and cost structures. This is now starting to deliver the business synergies including increased patient numbers and revenues from the Australian phytocannabinoid medicine division of the Company.

Nicole Godresse, MGC Pharma's Global Chief Sales Officer commented: "In recent months we have seen rapid sales growth of our medical cannabis products as a direct result of our strategy to broaden our core prescriber base, diversify and expand our revenue streams and build additional strategic alliances. It is pleasing to see these strategies starting to translate into positive commercial outcomes and we expect this strong growth momentum to continue in 2021 and beyond".

ArtemiCTM Rescue from Swiss PharmaCan AG

The first bulk order of ArtemiCTM Rescue delivered in March is part of a quarterly wholesale order quantity from SPC under the Master Agreement, which is to run for a minimum of 3 years. As announced on 18 February 2021, MGC Pharma signed an exclusive master supply and distribution agreement (the 'Master Agreement') with leading European nutraceutical producer and distributor, Swiss PharmaCan AG ("SPC") for the sale and distribution of the Company's food supplement ArtemiCTM Product line.

ArtemiCTM is a clinically tested food supplement (nutraceutical, dietary supplement, natural health product) containing four natural based ingredients consisting of Artemisinin, Curcumin, Boswellia serrata, and Vitamin C.

As the mechanism of action of ArtemiCTM Rescue is focused on the anti-inflammatory effect and reducing and prevention of cytokine storm, a wide spectrum of potential indications will be considered for future development.

The Master Agreement includes a minimum wholesale order quantity of 40,000 units per quarter. The Company will be responsible for providing ArtemiCTM Rescue to SPC and has the ability to produce commercial scale batches of both products through its current manufacturing capacity and production facility in Slovenia.

Roby Zomer, Co-founder and Managing Director of MGC Pharma, commented: "We are very pleased to complete our first batch purchase order for ArtemiCTM Rescue under our Swiss PharmaCan agreement. This, combined with sales growth of other pharma grade cannabinoid products in key markets, has helped to deliver the strongest month and quarter of revenue growth for the Company to date."

Nicole Godresse, Global Chief Sales Officer of MGC Pharma, commented: "The launch of ArtemiCTM Rescue represents a significant milestone for MGC Pharmaceuticals. We are encouraged by early clinical trial results and confident that ArtemiCTM Rescue will provide a highly effective and accessible over-the-counter, plant-based treatment option for patients, as well as contributing to the rapid acceleration of MGC Pharmaceutical's revenue growth in 2021 and beyond."

--Ends--

Authorised for release by the Board, for further information please contact:

MGC Pharmaceuticals Ltd

Roby Zomer

CEO & Managing Director

+61 8 6382 3390

info@mgcpharma.com.au

UK PR Tavistock - Tavistock

Charlies Vivian +44 20 7920 3150

Charles.Vivian@tavistock.co.uk

Tim Pearson +44 7983118 502

Tim.Pearson@tavistock.co.uk

UK Broker - Turner Pope

Andy Thacker

Andy.Thacker@TurnerPope.com

Zoe Alexander

Zoe.Alexander@TurnerPope.com

+44 20 3657 0050

Australian PR/IR Advisors - Media & Capital Partners

Rod Hinchcliffe (IR) +61 412 277 377

Rod.Hinchcliffe@mcpartners.com.au

About MGC Pharma

MGC Pharmaceuticals Ltd (LSE: MXC, ASX: MXC) is a European based bio-pharma company developing and supplying affordable standardised phytocannabinoid derived medicines to patients globally. The Company's founders were key figures in the global medical cannabis industry and the core business strategy is to develop and supply high quality phytocannabinoid derived medicines for the growing demand in the medical markets in Europe, North America, and Australasia. MGC Pharma has a robust product offering targeting two widespread medical conditions - epilepsy and dementia - and has further products in the development pipeline.

Employing its 'Nature to Medicine' strategy, MGC Pharma has partnered with renowned institutions and academia to optimise cultivation and the development of targeted phytocannabinoid derived medicines products prior to production in the Company's EU-GMP Certified manufacturing facility.

MGC Pharma has a number of research collaborations with world renowned academic institutions, and including recent research highlighting the positive impact of using specific phytocannabinoid formulations developed by MGC Pharma in the treatment of glioblastoma, the most aggressive and so far therapeutically resistant primary brain tumour.

MGC Pharma has a growing patient base in Australia, the UK, Brazil and Ireland and has a global distribution footprint via an extensive network of commercial partners meaning that it is poised to supply the global market.

Follow us through our social media channels:

Twitter: @MGC_Pharma

Facebook: @mgcpharmaceuticals

LinkedIn: MGC Pharmaceuticals Ltd.

Instagram: @mgc_pharma 

About Swiss PharmaCan AG

Micelle Technology AG, parent company of Swiss PharmaCan AG is a dynamic organization dedicated to R&D using natural active ingredients (i.e., vitamins and minerals) to improve human health. As one of the leading innovators of plant-based micelle concentrates, Micelle Technology AG offers a unique technology, which enables the company to harness the full potential of herbal active ingredients.

Website: www.swisspharmacan.ch 

 

 

 

[1] Excluded territories; Thailand, Myanmar, Israel, CIS (Armenia, Belarus, Kazakhstan, Moldova, Russia, Tajikistan, Uzbekistan) and Ukraine

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
MSCUPUWUCUPGUQM
Date   Source Headline
28th Mar 20249:12 amRNSPDMR Notification
28th Mar 20249:07 amRNSRefinancing of Convertible Securities Agreement
18th Mar 20248:23 amRNSResults of General Meeting
29th Feb 20249:36 amRNSHalf-year Report
19th Feb 20244:00 pmRNSUpdate - Application for Admission to Trading
13th Feb 202410:00 amRNSDispatch of General Meeting Documents
31st Jan 20247:30 amRNSDecember 2023 Quarter Activity Report
11th Jan 20249:54 amRNSDirector/PDMR Shareholding
22nd Dec 20239:09 amRNSCompany Update & Placing to Raise US$500,000
19th Dec 20237:57 amRNSArtemiCâ„¢ receives FDA Approval in Saudi Arabia
18th Dec 20239:06 amRNSNon-Deal Roadshow Presentation December 2023
1st Dec 20238:09 amRNSCorporate Update - Board and UK Adviser Changes
30th Nov 20239:08 amRNSResults of Shareholder’s Annual General Meeting
16th Nov 20231:51 pmRNSHolding(s) in Company
13th Nov 20239:15 amRNSHolding(s) in Company
9th Nov 202310:47 amRNSHolding(s) in Company
8th Nov 202311:52 amRNSHolding(s) in Company
8th Nov 202310:00 amRNSCapital Consolidation and US$7.9m Placement
1st Nov 202311:30 amRNSConsolidation and New Fund Raising
1st Nov 202311:03 amRNSMGC Secures US$7.9 Million In Firm Commitments
31st Oct 20239:32 amRNSDispatch of Annual General Meeting Documents
30th Oct 20237:16 amRNSSeptember 2023 Quarter Activity Report
25th Oct 20233:16 pmRNSResults of Shareholder’s General Meeting
9th Oct 202310:02 amRNSDate of AGM & Closing Date of Director Nominations
29th Sep 202310:40 amRNSAnnual Report for the year ended 30 June 2023
26th Sep 20237:36 amRNSLetter From the Managing Director
26th Sep 20237:35 amRNSDispatch of General Meeting Documents
12th Sep 20237:00 amRNSHolding(s) in Company
5th Sep 202312:34 pmRNSResults of Shareholder’s General Meeting
1st Sep 20237:30 amRNSChange of registry address notification
31st Aug 20238:44 amRNS30 June 2023 Preliminary Financial Report
30th Aug 20238:30 amRNSShare Purchase Plan Closed
15th Aug 20237:29 amRNSSPP – Extension of Closing Date
14th Aug 20237:00 amRNSPositive Pre-clinical Trial Results on CimetrA®
4th Aug 20239:10 amRNSDispatch of General Meeting Documents
3rd Aug 20232:23 pmRNSAustralian Prospectus & Share Purchase Plan
2nd Aug 202310:25 amRNSApplication for Admission to Trading
1st Aug 20238:56 amRNSMGC Pharma Launches Share Purchase Plan
31st Jul 20237:00 amRNSPermission for first import of Psilocybin
28th Jul 20239:05 amRNSResignation of Joint Company Secretary
28th Jul 20238:00 amRNSJune 2023 Quarter Activity Report and Cash Flow
21st Jul 202310:56 amRNSHolding(s) in Company
18th Jul 202311:41 amRNSPDMR Notification
14th Jul 20237:00 amRNS£0.7 million Fundraising
12th Jul 20237:00 amRNSFurther re AMC Places another $1M Order of ArtemiC
7th Jul 20237:00 amRNSAMC Places Another US$1M Order of ArtemiC™
3rd Jul 20237:00 amRNSReclassification of Psychedelic Compounds
30th Jun 20239:31 amRNSDetails of Company Address
30th Jun 20239:30 amRNSCompany Update
29th Jun 202310:22 amRNSResults of Shareholder’s General Meeting

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.